CATX Stock Summary and Trading Ideas (Perspective Therapeutics | AMEX:CATX)

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Perspective Therapeutics trades on the AMEX stock market under the symbol CATX.

As of December 26, 2025, CATX stock price climbed to $2.88 with 566,757 million shares trading.

CATX has a beta of 1.76, meaning it tends to be more sensitive to market movements. CATX has a correlation of 0.13 to the broad based SPY ETF.

CATX has a market cap of $214.09 million. This is considered a Small Cap stock.

Last quarter Perspective Therapeutics reported $209,000 in Revenue and -$.35 earnings per share. This fell short of revenue expectation by $-35,104 and missed earnings estimates by -$.03.

The top ETF exchange traded funds that CATX belongs to (by Net Assets): IWM, VTI, VXF, IWN, IBB.

CATX has underperformed the market in the last year with a return of -11.4%, while the SPY ETF gained +16.0%. In the last 3 month period, CATX fell short of the market, returning -11.7%, while SPY returned +4.7%. However, in the most recent 2 weeks CATX has outperformed the stock market by returning +12.9%, while SPY returned +0.7%.

CATX support price is $2.65 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CATX shares will trade within this expected range on the day.